Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

30.46 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Alkermes's Return On Capital Employed Overview
According to Benzinga Pro, during Q4, Alkermes (NASDAQ:ALKS) earned $873.00 thousand, a 103.01% increase from the preceding quarter. Alkermes also posted a total of $324.46 million in sales, a 10.31%... 
Via Benzinga
56 Biggest Movers From Yesterday
Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) gained 54.5% to close at $2.07 on Wednesday. Hookipa Pharma amended and restated collaboration and license agreement with Gilead... 
Via Benzinga
Why Are Alkermes Shares Trading Higher Today?
Alkermes plc's (NASDAQ: ALKS) Q4 sales increased 16% Y/Y to $324.5 million, beating the consensus of $308.69 million. Net sales of proprietary products were $178.9... 
Via Benzinga
Recap: Alkermes Q4 Earnings
  Alkermes (NASDAQ:ALKS) reported its Q4 earnings results on Wednesday, February 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For February 16, 2022
Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on revenue of $331.16 million. 
Via Benzinga
Alkermes Has Launched Employee Resource Groups
SOURCE: Alkermes 
Via 3BL Media
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) jumped 52.8% to $2.0478. Hookipa Pharma amended and restated collaboration and license agreement with Gilead Sciences for arenaviral... 
Via Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following... 
Via Benzinga
One Overdose Is Too Many
SOURCE: Alkermes 
Via 3BL Media
Earnings Preview For Alkermes
Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that Alkermes will... 
Via Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news... 
Via Benzinga
Alkermes Schizophrenia Med Shows Lower Mean Weight Gain In Early Illness With Schizophrenia
Alkermes plc's (NASDAQ: ALKS) ENLIGHTEN-Early Phase 3b study of Lybalvi (olanzapine & samidorphan)  
Via Benzinga
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2022
Upgrades 
Via Benzinga
BioCorRx Aims To Help Combat Opioid Crisis With Implantable Naltrexone Drug Candidate BICX104
Image provided by BioCorRx of a naltrexone pellet This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be... 
Via Benzinga
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In... 
Via Benzinga
Early Monday Report - More Moves Out Of China
Before it even turned Monday in the West, China insurers are feeling the heat. 
Via Talk Markets
Happy New Year - Sunday Edition
Starting a new year - we look at tech, pharma and mining stocks and their goings-on. 
Via Talk Markets
Our Collective Responsibility to Respond Effectively to the Climate Crisis
SOURCE: Alkermes 
Via 3BL Media
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2021
Upgrades Goldman Sachs upgraded the previous rating for Grupo Aeroportuario del Sureste SAB de CV 
Via Benzinga
Alkermes in Action: Giving Tuesday
SOURCE: Alkermes 
Via 3BL Media
Alkermes Celebrates National Family Caregivers Month
SOURCE: Alkermes 
Via 3BL Media
75 Biggest Movers From Yesterday
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Check out these big penny stock gainers and losers... 
Via Benzinga
Janssen Partially Terminates Nanoparticle License Agreement With Alkermes
Alkermes plc (NASDAQ: ALKS) stock is trading lower after announcing that Janssen, a unit of Johnson & Johnson (NYSE: JNJ), has provided notice of its... 
Via Benzinga
Why Alkermes Stock Is Sinking Today
Johnson & Johnson partly ended two licensing agreements with the company. 
Via The Motley Fool
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
7 A-Rated Healthcare Stocks to Buy for the Long Haul
It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future. 
Via InvestorPlace
10 Biggest Price Target Changes For Thursday
Oppenheimer lowered Teladoc Health, Inc. (NYSE:TDOC 
Via Benzinga
Alkermes plc (ALKS) Q3 2021 Earnings Call Transcript
ALKS earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been... 
Via FinancialNewsMedia
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.